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Background: Antimicrobial peptides (AMPs) are an ancient group of defense molecules. AMPs are widely
distributed in nature (being present in mammals, birds, amphibians, insects, plants, and microorganisms). They
display bactericidal as well as immunomodulatory properties. The aim of this study was to investigate the
antimicrobial and anti-inflammatory activities of a combination of two AMPs (temporin B and the royal jellein I)
against Staphylococcus epidermidis.
Results: The temporin B (TB-KK) and the royal jelleins I, II, III chemically modified at the C terminal (RJI-C, RJII-C,
RJIII-C), were tested for their activity against 10 different Staphylococcus epidermidis strains, alone and in
combination. Of the three royal jelleins, RJI-C showed the highest activity. Moreover, the combination of RJI-C and
TB-KK (MIX) displayed synergistic activity. In vitro, the MIX displayed low hemolytic activity, no NO2
- production and
the ability to curb the synthesis of the pro-inflammatory cytokines TNF-α and IFN-γ to the same extent as
acetylsalicylic acid. In vivo, the MIX sterilized mice infected with Staphylococcus epidermidis in eleven days and
inhibited the expression of genes encoding the prostaglandin-endoperoxide synthase 2 (COX-2) and CD64, two
important parameters of inflammation.
Conclusion: The study shows that the MIX – a combination of two naturally occurring peptides - displays both
antimicrobial and anti-inflammatory activities.Background
Coagulase-negative staphylococci (CoNS) are highly abun-
dant on the human skin, already a few hours after birth.
The CoNS Staphylococcus epidermidis is an ubiquitous
and permanent colonizer of human skin and the first
cause of nosocomial infections [1]. Most infections with
high morbidity and mortality are caused by methicillin-
resistant strains of Staphylococcus epidermidis (MRSE)
[2,3]. In addition, many MRSE strains form a capsule
which favors biofilm development, where the pathogen
can persist protected from antibiotics and invisible to
the immune system [4,5].
New, unconventional antimicrobials are therefore ur-
gently needed [6,7]. In this context, antimicrobial peptides* Correspondence: capparel@unina.it
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reproduction in any medium, provided the or(AMPs), in their natural form or after chemical modifica-
tion, display interesting features as candidates to become
new antimicrobials. They have a broad spectrum of activ-
ity against Gram-positive and Gram-negative bacteria,
can be easily synthesized in laboratory and have limited
toxicity for eukaryotic cells [8,9]. As innate immune
components, AMPs lack specificity and immune mem-
ory, with the consequence that the pathogens rarely de-
velop resistance to them [10]. Importantly, AMPs rapidly
intercept and kill pathogens [11]. AMPs differ each other
by size, sequence and secondary structure (α-helix or β-
sheet) [12]. Most of them are hydrophobic and amphi-
pathic [13]. AMPs can exert their activity by disrupting
the membrane [14] or passing through the bacterial
membrane [15]. Molecules belonging to the former class
of AMPs permeabilize the membrane phospholipids bi-
layer and kill the bacterial cell; those belonging to the
latter class pass through the bacterial membrane andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as traditional antibiotics. AMPs, in addition to the anti-
microbial activity, display also immune-modulatory
properties (such as chemiotaxis, which contributes to
bacterial elimination) and interact with natural and adap-
tive immunity [16,17]. Thus, in view of the above proper-
ties, AMPs represent one of the most promising future
strategies for combating infections and microbial drug
resistance. The present study describes two chemically
modified AMPs - an analogue of the temporin B
(TB-KK) secreted by the granular glands of the European
red frog (Rana temporaria) [18] and an analogue of the
royal jellein I (RJI-C) secreted by the mandible and hypo-
pharyngeal glands of honeybees (Apis mellifera) [9,19].
These two peptides behave differently towards the bac-
terial membrane. RJI-C folds into beta sheets and aggre-
gates onto the membrane; TB-KK folds into an alpha
helix and does not aggregate onto the membrane [8,9].
Recent data demonstrate that hydrophobic peptides,
when mixed with peptides possessing a net posi-
tive charge, give origin to a mixture with potential anti-
bacterial activity [20,21]; second, that the combination of
antimicrobial peptides derived from different organisms
are highly active against Gram positive bacteria [9]. In
agreement with these results, here we show that a mix-
ture of TB-KK and RJI-C – two AMPs derived from differ-
ent sources - displays strong antimicrobial activity against
Gram-positive bacteria - modulates pro-inflammatory cy-
tokines and nitric oxide production, in vitro and in vivo.
The two peptides, following chemical modification, po-
tentially can be made available in large quantities and in
a homogeneous and highly pure form.
Results
Characterization of Staphylococcus epidermidis strains
To establish the clonal origin of the Staphylococcus epi-
dermidis strains used in the study, the strains (10) were
characterized phenotypically - with respect to their anti-
biotic resistance pattern and molecularly with respect to
their Restriction Endonucleases Analysis (Pulse Field Gel
Electrophoresis - REA-PFGE) pattern. All strains re-
sulted resistant to aztreonam (30 μg; ATM30), bacitracin
(10 μg; B2), cloxacillin (1 μg; CX1) and metronidazole
(80 μg; M80) and sensitive to imipenem (10 μg; IPM10).
The remaining 25 antibiotics displayed a strain specific
pattern (Table 1). Also, with one exception (the strain
SE), the strains displayed all different macro-restriction
patterns, when analyzed by Sma I REA-PAGE (Figure 1).
Thus, the strains used in this study belong to different
clonal lineages.
In vitro antimicrobial activity of TB-KK and RJI-C
To evaluate the antimicrobial activity of RJI-C, RJII-C,
RJIII-C and TB-KK (Table 2) these AMPs were testedin vitro [8,9], individually and in combination, against
10 Staphylococcus epidermidis strains. Among the three
royal jelleins, RJI-C showed the highest activity (MIC:
30 μg/ml) (Table 3). Tested in various combination (RJI-C
at 20 μg/ml and RJII-C at 5–20 μg/ml ; RJI-C at 20 μg/ml
and RJIII-C at 5–20 μg/ml; RJII-C at 20 μg/ml and RJIII-C
at 5–20 μg/ml), the royal jelleins did not display synergis-
tic effects. Only RJI-C was thus tested for synergism with
TB-KK. The combination of the two antimicrobials –
RJI-C at 9 μg/ml and TB-KK at 6 μg/ml (MIX) – displayed
a fractional inhibitory concentration index ≤ 0.5, which
is evidence of synergism [20] (Table 3). The strains
of Staphylococcus epidermidis were all sensitive to the
MIX, but not its components (Table 4). This conclu-
sion is supported by the larger inhibition ring of
the MIX, compared to that of the individual components
(Figure 2A).
Interestingly, the antibacterial activity of the MIX
against probiotics bacteria (Lactobacillus plantarum,
Lactobacillus Paracasei, Bifidobacterium animalis) was
five-fold lower than that of gentamicin (Table 5).
In vitro hemolytic and cytotoxic activities of the MIX
To test the cytotoxic activity of the MIX, we used the
hemolytic and the LC50 assays. The MIX lysed less than
12% of the murine erythrocytes (data not shown) and
the LC50 value was 143,8 mg/ml versus 58.5 μg/ml of
TB-KK and 64.6 μg/ml of RJI-C (Additional file 1: Table
S1). The MIX was not toxic towards the macrophage
J774 cells, which remained vital at 72 hours (Figure 2B).
In vitro the MIX does not induce synthesis of NO-2
The MIX (RJI-C at 9 μg/ml and TB-KK at 6 μg/ml) did
not induce NO2
- synthesis in J774 cells. Rather, when
these cells were stimulated with LPS (10 μg/ml/well for
3 hours) and then treated with the RJ-IC, TB-KK and
MIX reduced NO2
- synthesis (Table 6), one of the para-
meters to determine the cellular toxicity.
In vitro anti-inflammatory activity of the MIX
To investigate whether the MIX, in addition to the anti-
microbial activity, also displays anti-inflammatory activ-
ity, J774 cells (106 cells/well) were stimulated with either
LPS or LTA (0.1, 1 or 10 μg/ml) for 3 hours. The results
show that LPS stimulates inflammation in the J774 cells
better than LTA (Figure 3A). Later, J774 cells were trea-
ted with gentamicin (5 μg/ml), acetylsalicylic acid (ASA,
5 μg /ml) or MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml)
for 3 hours. In the absence of the agent causing inflam-
mation (LPS), the MIX, gentamicin and ASA do not in-
duce inflammation (Figure 3B). In J774 cells (106 cells/
well) stimulated with LPS for 3 hours, the MIX curbs
the synthesis of the pro-inflammatory cytokines TNF-α
Table 1 Results of antibiotic susceptibility tests of ten Staphylococcus epidermidis strains
Antibiotics tested
Strain FD10 P120 AMX25 AM10 ATM30 B2 CB100 CD30 FOX30 CAZ30 A30 CX1 K15 FF50 GM10 IPM10 MY2 M80 MZ75 NET30 FM300 NB30 T30 P10 PIP100 RF30 SP100 RL100 TE30 VA30
SE R R R R R R R R I S I R R S R S R R R R R R I R R R R R R R
3/28 R I S S R R R S S I I R R R R S R R S I S S S R S S S R I I
2/2 S R R R R R R R R I S R R R I S R R R I S S S R R I R R I I
5/6 I R I R R R I R I S I R R R I S I R R I S S S R R S I R I I
5/8 S R I R R R I R I I R R R S R S R R R I S S R R R S S R S S
12/14 S R R R R R I R S S R R R R R S S R R I S S R R R R I R R I
9/1 S R R R R R I R S I S R S S I S S R R S S S S R R S I R S I
10/28 S I R R R R R R S I R R R S R S S R R I S S R R R S I R I I
12/26 S R R R R R R R S I S R S S R S S R R I S S S R R S I R S I
5/25 S R R R R R R R S I S R R I I S R R R I S S S R R S I R S S
R= strain resistant to the antibiotic.
S= strain sensitive to the antibiotic.
I= intermediate strains sensitive to the antibiotic.
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Table 2 Peptide sequences and mass analysis of the royal
jelleins (RJ) and temporin (TB) used in the study
Peptide Sequence Calc. mass (DA) Meas. mass (DA)
RJI-C PFKIDIHLGGY-NH2 1230.46 1231.02
RJII-C TPFKISIHLGGY-NH2 1331.56 1331.90
RJIII-C EPFKISIHLGGY-NH2 1359.57 1360.10
TB YLLPIVGNLLKSLL-NH2 1391.80 1391.20
TB-KK. KKYLLPI VGNLLKSLL-NH2 2295.40 2294.30
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same extent of the ASA (Figure 3C).
These experiments demonstrate that the MIX exerts
anti-inflammatory as well as antimicrobial activities, while
the single components of the MIX have no anti-
inflammatory activity (Additional file 2: Figure S1). Since
COX-2 is a well-established parameter of inflammation
[22] , the J774 cells were stimulated with LPS (10 μg/ml)
and 1 hour later treated with the MIX, RJII-C (non-active
peptide), acetylsalicylic acid (ASA), gentamicin or vehicle
(PBS) for 3 hours. The level of the COX-2 protein was
then detected by western blot. The MIX-treated cells, dis-
played a COX-2 protein level comparable to that of the
cells treated with ASA or gentamicin, and much lower
than that of the cells treated with RJII-C or the vehicle
(Figure 3D). The above results demonstrate that the MIX
curbs inflammation to the same extent as ASA [23].
In vivo anti-inflammatory activity of the MIX in mice
stimulated with LPS
To investigate further the property of the MIX to
curb inflammation in vivo, LPS (250 μg, ~10 mg/Kg)Figure 1 Sma I REA (Restriction Endonucleases Analysis)-PFGE pattern
(Invitrogen); 2) strain 5/25; 3) strain9/1; 4) strain 2/2; 5) strain 10/28; 6
strain SE (untypable); 11) strain 3/28; 12) Lambda DNA - Hind III Dige
(Bio-Rad); 14) PFGE marker, 0.225–2.2 Mb S. cerevisiae chromosomalwas administrated to four groups of mice (3 mice/
group). After 3 hours, the groups were treated re-
spectively with the MIX (RJI-C 9 μg/mouse + TB-KK
6 μg/mouse), gentamicin (5 μg in 100 μl/mouse) or
ASA (5 μg in 100 μl/mouse). The last group received
100 μl of saline buffer as control. After 3 hours, the
mice that received the MIX showed a reduced level
of both the pro-inflammatory cytokines TNF-α and
IFN-γ, when compared to gentamicin-treated group,
but an higher expression level of IFN- γ, when com-
pared to the ASA group (Figure 3E). In conclusion,s of Staphylococcus epidermidis strains: 1) 1Kb plus DNA Ladder
) strain 12/14; 7) strain 5/8; 8) strain 12/26; 9) strain 5/6; 10)
sted (Invitrogen); 13) DNA Size Standards - Lambda Ladder
DNA (Bio-Rad).
Table 3 The FIC index against Staphylococcus
epidermidis strains: ≤ 0.5, synergy ; >0.5, no interaction
Antimicrobial peptides MIC100 Fic index
RJI-C 30 μg/ml (24 μM)
RJII-C 200 μg/ml (150 μM)
RJIII-C 300 μg/ml (220 μM)
TB-KK 7 μg/ml (3 μM)
Gentamicin 5 μg/ml (10 μM)
RJI-C + TB-KK 9 μg/ml + 6 μg/ml
(7.3 μM + 2.6 μM)
0.5
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http://www.biomedcentral.com/1471-2172/13/61the MIX performs better than gentamicin, but worse
than ASA.In vivo antimicrobial efficacy of the MIX given
intravenously at 12 hours post infection
To evaluate the efficacy of the MIX to contrast microbial in-
fection, four groups of mice (15 mice/group) were infected
with lethal dose (108 CFU/mouse) of Staphylococcus epi-
dermidis (SE). This strain was chosen since it is resistant
to the majority of the antibiotics tested (Table 1).
One group did not receive any treatment (control
group); a second group received sterile PBS (100 μl/
mouse) (placebo group – data not shown); the third
group received the MIX (RJI-C 9 μg/mouse + TB-KK
6 μg/mouse); the fourth group received gentamicin
(5 μg/mouse). PBS, MIX and gentamicin were adminis-
tered intravenously at 3 hours post infection. In both,
placebo and control groups, the bacterial load of kidneys
and spleens increased progressively, while it decreased
in the groups treated with gentamicin or the MIX
(Additional file 3: Figure S2). Upon treatment of the
mice with the MIX, the acute phase proteins, which
represent important markers of inflammation [24],
were evaluated (Additional file 4: Table S2). The SAA
(Serum amyloid A), haptoglobin and fibrinogen were
within normal ranges in the mice treated with the MIX orTable 4 Antimicrobial activity of the MIX and its components
Strains % inhibition of bacterial growth
RJI-C 9 μg/ml (7.3 μM)
% inhibition of bacterial gr
TB-KK 6 μg/ml (2.6 μM
3/28 17 ± 2 19 ± 2
2/2 18 ± 1 23 ± 0.5
5/6 4 ± 3 10 ± 1
5/8 12 ± 2 21 ± 2
12/14 11 ± 0.5 20 ± 3
9/1 18 ± 0 26 ± 2
10/28 0 4 ± 1
12/26 19 ± 2 14 ± 2
5/25 15 ± 1 21 ± 1with gentamicin, while significantly high in the control
mice (infected but not treated) (Additional file 4: Table S2).In vivo anti-inflammatory efficacy of the MIX given
intravenously at 12 hours post infection
The four groups of mice described before have been
used also to evaluate the anti-inflammatory activity of
the MIX. For this purpose, the expression levels of the
TNF-α , IFN-γ, IL-10 cytokine genes were measured at 3,
6 and 9 hours after treatment in the kidney samples
(Figure 4A-C, respectively). In the group treated with the
MIX, the TNF-α and IFN-γ were under expressed (at 6,
9 hours from treatment), as compared to the group treated
with gentamicin (Figure 4A-C). This result suggests that
the MIX controls inflammation better than gentamicin.
Also CD64 and COX-2 markers of inflammation
in vivo were evaluated. Blood samples were collected 3,
6, or 9 hours after the treatments. CD64 was measured
by flow cytometry (Figure 5A). Six and nine hours after
the treatment with gentamicin or the MIX, the mice
displayed a decreased expression of the CD64 marker
(Figure 5A). The level of COX-2, was evaluated by RT-
PCR on the mRNA extracted from kidney samples. In
control mice displayed a significantly higher expression
level of COX-2, compared to the mice treated with MIX
or gentamicin. In the control mice COX-2 peaked 3 hours
after the treatment. In the mice treated with gentamicin
or the MIX, COX-2 expression level returned to the nor-
mal level nine hours after the treatment (Figure 5B).
To verify whether the MIX affected granulocytic infil-
tration in the kidneys of infected mice, hematoxylin-
eosin staining was performed. As expected, kidneys of
control mice displayed granulocytic infiltration within
the lumen of the cortical convoluted tubules and hence
lymphocytic infiltration, vessel activation and glomerular
hyperplasia (Figure 6 panel 1, 5). Instead, kidneys of
MIX-treated mice showed a dramatic reduction in the
number of granulocytic cells localized in the corticalagainst different strains of Staphylococcus epidermidis
owth
)
% inhibition of bacterial growth RJI-C 9 μg/ml + TB-KK
6 μg/ml (RJI-C 7.3 μM + TB-KK 2.6 μM) (MIX)
91 ± 1
96 ± 2
100 ± 0
95 ± 2
92 ± 1
96 ± 2
100 ± 0
100 ± 0
90 ± 2
Figure 2 (A) Antimicrobial activity of the single peptides (RJI-C 9 μg/ml; RJII-C 15 μg/ml; TB-KK 6 μg/ml) and of MIX (RJI-C at 9 μg/ml
and TB-KK at 6 μg/ml) are shown as inhibition zone assay. A larger zone of inhibition is evident around the MIX compared to the single
components. (B) J774 cell line treated with the single peptides (RJI-C 9 μg/ml; RJII-C 15 μg/ml; TB-KK 6 μg/ml) or the MIX (RJI-C at 9 μg/ml and
TB-KK at 6 μg/ml) maintain the same growth rate compare to the untreated control.
Capparelli et al. BMC Immunology 2012, 13:61 Page 6 of 14
http://www.biomedcentral.com/1471-2172/13/61convoluted tubules, less glomerular hyperplasia, and no
lymphocyte infiltration (Figure 6 panel 2–4).In vivo antimicrobial efficacy of the MIX for the period
of 12 days
To test the antimicrobial activity of the MIX in vivo for
a longer period, mice were infected with a sub-lethal
dose (107 CFU/mouse) of Staphylococcus epidermidis
and then treated with the MIX. Four groups of mice (24
mice/group) were infected with the bacterial strain (SE).
One group of mice did not receive any treatment (con-
trol group); a second group received sterile PBS (100 μl/
mouse) (placebo group); the third group received the
MIX (RJI-C: 9 μg/mouse + TB-KK: 6 μg/mouse); the
fourth group received gentamicin (5 μg/mouse). PBS,
MIX and gentamicin were administered intravenously in
three boosts 3, 6 and 9 days post infection. In the pla-
cebo and the control groups, the bacterial load of kid-
neys and spleens (the target organs of the pathogen)
increased progressively, while the load was significantly
lower in the groups treated with gentamicin or the MIX.
Eleven days after the infection, the mice treated with
gentamicin were still infected, while those treated with
the MIX were already sterile (Figure 7A-B).Table 5 Antimicrobial activity of the MIX or gentamicin
on probiotic bacteria
Strains MIX RJI-C 9 μg/ml
+TB-KK 6 μg/ml
(RJI-C 7.3 μM +TB-KK
2.6 μM)
Gentamicin
5 μg/ml
(10 μM)
Bifidobacterium
animalis
29% ± 3 96% ± 4
Lactobacillum
plantarum
23% ± 2 97% ± 4
Lactobacillum
paracasei
25% ± 2 96% ± 3Four days after the infection, in addition to spleen and
kidneys (106 CFU/gr and 107 CFU/gr respectively), the
bacterium was also detected (at a threshold level:
102 CFU/g) in the liver (data not shown). Thus, the MIX
is slightly more effective than gentamicin (Figure 7A-B).
In all four groups, bacteria were no longer detected
in the blood circulation within 2 h from infection
(Additional file 5: Figure S3).
In vivo anti-inflammatory efficacy of the MIX for the
period of 12 days
To evaluate the anti-inflammatory activity of the MIX,
the expression levels of the TNF-α, IFN-γ, IL-10 cyto-
kines genes were measured in the kidneys. The experi-
ment was carried out on the same four groups of mice
described in the previous paragraph. For this purpose,
the expression levels of the cytokines were measured 24
and 48 hours after each treatment with MIX (or 4, 5, 7,
8,10 and 11 days post infection). In the group treated
with the MIX, compared to the group treated with genta-
micin, the TNF-α and IFN-γ levels were under expressed
(at 7 days) while the IL-10 levels were over expressed (at
10 days) (Figure 7C). This result suggests that the
MIX controls inflammation better than gentamicin.
Discussion
Recently we demonstrated that new antimicrobials are
more effective than traditional antibiotics against Staph-
ylococcus epidermidis [25,26]. The present study extends
these results, providing evidence that the MIX – a mix-
ture of a royal jellein modified at the C-terminal (RJI-C)
and an analogue of temporin B (TB-KK) – is a valid al-
ternative to the use of gentamicin against skin infections
caused by Staphylococcus epidermidis.
In vivo, endogenous antimicrobial peptides (such as
human defensins and cathelecidins) are known to be
pleiotropic: they act as antimicrobials [27]; neutralize
Table 6 NO2
- production of J774 cells: Mouse macrophages untreated, treated with RJI-C, TB-KK or the MIX, stimulated
with LPS, stimulated with LPS and treated with RJI-C, TB-KK or the MIX
Treatment Time of incubation (h)
24 48 72
No treatment 0.25 ± 0.04 0.69 ± 0.02 0.92 ± 0.2
RJI-C (15 μg/ml) (12 μM) 0.42 ± 0.03 0.75 ± 0.01 1.02 ± 0.3
TB-KK (15 μg/ml) (6.5 μM) 0.82 ± 0.05 1.25 ± 0.2 1.34 ± 0.2
MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml) (RJI-C 7.3 μM + TB-KK 2.6 μM) 0.72 ± 0.3 0.85 ± 0.3 1.06 ± 0.2
LPS (10 μg/ml) 2.93 ± 0.2 10.96 ± 0.4 12.16 ± 0.5
LPS + RJI-C (15 μg/ml) (12 μM) 2.85 ± 0.3 8.42 ± 0.1 10.21 ± 0.2
LPS + TB-KK (15 μg/ml) (6.5 μM) 3.12 ± 0.6 9.75 ± 0.1 11.45 ± 0.2
LPS + MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml) (RJI-C 7.3 μM + TB-KK 2.6 μM) 2.63 ± 0.4 7.25 ± 0.3 8.26 ± 0.1
Data are expressed as micromoles of NO2- for 106 input cells, and are means ± standard deviation of three different experiments each performed in triplicate.
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would induce an excess of inflammation and tissue dam-
age [28,29]; attract inflammatory cells to the wound site
and promote wound healing.
The two exogenous components of the MIX also behave
in a pleiotropic fashion: they control the bacterial load
(Figure 7A-B and Additional file 3: Figure S2), inhibit the
synthesis of pro-inflammatory cytokines (Figures 4 and
7C) and control the expression of COX-2 (Figures 3D
and 5B), the acute phase proteins (Additional file 4:
Table S2) and the expression of the CD64 receptor
(Figure 5A). At the histological level, the MIX reduces
kidney lymphocyte infiltration (Figure 6).
Mice infected with a sub-lethal dose of Staphylococcus
epidermidis and three days later treated with the MIX
(RJI-C: 9 μg/mouse + TB-KK: 6 μg/mouse), within 11 days
from treatment, displayed sterile kidneys and spleen –
the organs targeted by the bacterial strain used in this
study (Figure 7A-B). Samples collected at 15 min inter-
vals from infection showed that bacteria leave the blood
circulation within 2 h (Additional file 5: Figure S3). These
results are clinically relevant since they suggest that the
MIX can potentially be used in humans, where infection
is generally caused by a small initial inoculum and treat-
ment is therefore initiated several days after infection
(Figure 7A-B).
The MIX is not toxic for eukaryotic cells, in vitro and
in vivo (Figure 2B); its components act synergistically
(Figure 2A) and becomes moderately hemolytic (12%).
In addition, the MIX reduces the synthesis of NO2
- in
cells infected with Staphylococcus epidermidis (Table 6).
These additional properties make the MIX a candidate
for a new generation drug.
In vitro and in vivo experiments demonstrate that the
MIX down regulates the level of the pro-inflammatory
cytokines TNF−α and IFN-γ while enhancing the ex-
pression of the anti-inflammatory cytokine IL-10. This
effect is comparable to that of gentamicin, a well-knownantimicrobial drug. These results confirm that the MIX,
in addition to an antibacterial activity, also exerts –
in vivo and in vitro - an anti-inflammatory activity.
The intestinal flora represents a defense barrier
against pathogens [30]. We therefore also investigated
whether the MIX spared probiotic bacterial species
in vitro. While gentamicin killed the totality of the pro-
biotics tested (Lactobacillus plantarum, Lactobacillus
Paracasei, Bifidus animalis), the MIX killed a minority
of each bacterial species (29%-23%-25%, respectively)
(Table 5).
The influence of the MIX on the major cell signal-
ing pathways was also studied. CD64 and COX-2
warn about the cell exposure to inflammatory stimuli
[31,32]. The MIX reduced the expression level of
COX-2 (Figures 3D and 5B) and CD64 (Figure 5A),
proofing that the MIX exerts also anti-inflammatory
activity. The CD64 levels are high in the mice
infected. In the mice infected and then treated with
MIX at both 3, 6 and 9 hours from treatment, levels
of CD64 are reduced (Figure 5A). This last result pro-
vides evidence that the MIX has effects on mechan-
isms of both innate and adaptive immunity.
Conclusions
This study provided evidence which suggests an analogy
between endogenous AMP and the MIX, consisting of
exogenous and chemically modified AMPs. Both display
a two-fold role, rapidly recognizing the presence of a
pathogen and preventing an excess of inflammation.
Methods
Bacteria
List and origin of Staphylococcus epidermidis used in
this study is reported in Additional file 6: Table S3. All
strains were isolated from patients hospitalized at the
Medical School of the University of Naples Federico II.
All strains were molecular identified by means of kat
Figure 3 (A) TNF-α, IFN-γ, IL-10 mRNA expression levels in J774
cells stimulated with LPS or LTA (0,1,1 or 10 μg/ml) for 3 hours.
(B) J774 cells treated with gentamicin (5 μg/ml) or MIX (RJI-C
9 μg/ml + TB-KK 6 μg/ml) or ASA (5 μg/ml) for 3 hours. (C) J774
cells stimulated with LPS (10 μg/ml) for 3 hours and treated with
gentamicin (5 μg/ml) or MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml) or ASA
(5 μg/ml) for further 3 hours. (D) Western blot analysis of COX-2 in
J774 cell line. Lane 1–3: J774 cells + LPS(10 μg/ml); Lane 4–6: J774
cells + LPS (10 μg/ml) + inactive peptide (RJII-C 15 μg/ml);
Lane 7–9: J774 cells + LPS (10 μg/ml) + ASA (5 μg/ml); Lane 10–12:
J774 cells + LPS (10 μg/ml) + MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml;
Lane 13–14: J774 cells + LPS (10 μg/ml) + gentamicin (5 μg/ml).
(E) TNF-α, IFN-γ, IL-10 mRNA expression levels in kidney of mice
(3mice/group) stimulated with LPS (250 μg, ~10 mg/Kg) for 3 hours;
stimulated with LPS (250 μg, ~10 mg/Kg) for 3 hours and treated
with gentamicin (5 μg/mouse) or MIX (RJI-C 9 μg/mouse + TB-KK
6 μg/mouse) or ASA (5 μg/mouse) for 3 hours. Values were
normalized with GAPDH and compared to untreated control.
*P <0.05, **p < 0.01; ***p < 0.001, Student’s t test gentamicin vs MIX
and gentamicin vs ASA.
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[33].
The study does not investigate clinical aspects of the
disease, nor it uses human specimen. The study there-
fore does not require the Ethic Committee approval.Antibiotic susceptibility of Staphylococcus epidermidis strains
The antibiotic-susceptibility profile of strains was tested
using the disk diffusion method on Mueller-Hinton agar,
according to the NCCLS guidelines (2002) [34]. The an-
tibiotics used and their concentrations were as follows:
amoxicillin (25 μg; AMX25), ampicillin (10 μg; AM10),
aztreonam (30 μg; ATM30), bacitracin (10 μg; B2), car-
benicillin (100 μg; CB100), ceftazidime (30 μg; CAZ30),
cefoxidin (30 μg; FOX30), cephaloridine (30 μg; CD30),
cloxacillin (1 μg; CX1), erythromycin (15 μg; E15), fosfo-
mycin (50 μg; FF50), fusidic acid (10 μg; FD10), gentamicin
(10 μg; GM10), imipenem (10 μg; IPM10), lincomycin
(2 μg; MY2), metronidazole (80 μg; M80), mezlocillin
(75 μg; MZ75), netilmycin (30 μg; NET30), nitrofurantoin
(300 μg; FM300), novobiocin (30 μg, NB30), oxytetracyc-
line (30 μg, T30), penicillin-G (10 μg; P10), piperacillin
(100 μg, PIP100), rifampicin (30 μg; RF30), chlorotetracy-
cline (30 μg; A30), spiramycin (100 μg; SP100), sulfa-
methoxazole (100 μg; SP100), tetracycline (30 μg; TE30),
and vancomycin (30 μg; VA30). All antibiotics were pro-
vided by BioMérieux SA, (Marcy l’Etoile, France).
Pulsed-field electrophoresis of Staphylococcus epidermidis
strains
The procedure adopted was that described [35]. Briefly,
inserts of intact DNA were digested in 200 μl of appro-
priate buffer supplemented with 40 U of Sma I (Promega,
Milan). Pulsed field gel electrophoresis (PFGE) of the re-
striction digests was performed by using the CHEF sys-
tem (Bio-Rad Laboratories, Hercules, CA, USA) with 1%
(wt/vol) agarose gels and 0.5 x TBE as running buffer, at
10°C. Restriction fragments were resolved in a single run, at
constant voltage of 6 V cm2 and an orientation angle of
120° between electric fields, by a single phase procedure
for 24 h with a pulse ramping between 1 and 50s.
Figure 4 (A-C) TNF-α, IFN-γ, IL-10 mRNA expression levels in
infected mice with Staphylococcus epidermidis (108 CFU/mouse)
or infected with Staphylococcus epidermidis (108 CFU/mouse)
and treated with the MIX (RJI-C at 9 μg/mouse and TB-KK at
6 μg/mouse) or gentamicin (5 μg/mouse) at 3(A), 6 (B) and 9 (C)
hours after treatment. Values were normalized with GAPDH and
compared to untreated control. *P <0.05, **p < 0.01; ***p < 0.001,
Student’s t test gentamicin vs MIX.
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Antibacterial activity of the peptides used in this work was
evaluated as described previously [8]. A potential syner-
gism (FIC) between TB-KK and RJI-C (MIX) was evalu-
ated by adding combinations of two peptides in a serial
two-fold dilutions (RJI-C 5–100 μg, 40 μl/well; TB-KK 5–
100 μg, 40 μl/well;) to wells containing 105 CFU/well in
60 μl [8]. The fractional inhibitory concentration (FIC)
index for combinations of two peptides was calculated
according to the equation: FIC index = FICA + FICB = A/
MICA + B/MICB , where A and B are the MICs of drug
A and drug B in the combination, MICA and MICB are
the MICs of drug A and drug B alone, and FICA and FICB
are the FICs of drug A and drug B. The FIC indices wereinterpreted as follows: ≤0.5, synergy; 0.51–4.0, no inter-
action; > 4.0, antagonism [23].
The growth inhibition percentages of Staphylococcus
epidermidis and probiotic strains were assessed under
the same conditions.
Inhibition zone assay and test of the haemolytic activity
of the antimicrobials
The MIX (RJI-C at 9 μg/ml and TB-KK at 6 μg/ml) was
tested for its haemolytic activity using mouse red blood
cells and for inhibition zone assay test [8]. The MIX was
tested for its haemolytic activity using mouse red blood
cells. The blood was collected from the tail of the animals
and centrifuged (4x102 g for 3 min). The erythrocytes were
washed with saline, suspended at 3x106 erythrocytes/ml,
mixed with the peptide combination (RJI-C 9 μg and TB-
KK 6 μg in 100 μl saline) and incubated for 1 h at 37°C.
The haemolytic activity was measured according to the
formula OD peptide - OD negative control/OD positive control -
OD negative control X 100 where the negative control (0%
haemolysis) was represented by erythrocytes suspended
in saline and the positive control (100% haemolysis) was
represented by the erythrocytes lysed with 1% triton
X100 [36].
The LC50 values relative to the two peptides and the
MIX were calculated as described [37].
Cell culture
J774 murine macrophages from the American Tissue
Culture Collection (ATCC, Rockville, MD,USA) were
cultured in Dulbecco's modified Eagle's medium (DMEM,
Cambrex Bio Science, Verviers, Belgium). Culture media
contained 10% fetal bovine serum (FBS, Sigma, Milan,
Italy), 100 IU/ml penicillin, 100 μg/ml streptomycin (all
from Gibco, Paisley, Scotland). Cells were seeded on 96-
well plates (Falcon, Milan) for the MTT Assay, and on
24-well plates (Falcon, Milan) for NO2
− measurements,
fluorescence microscopy analysis, and RT-PCR assays.
Cell monolayers were grown to adherence before the
experiments were started.
Mice
Experiments were carried out on female BALB/c mice
(aged 8 to 10 weeks) at the animal facility of the Univer-
sity of Naples. Bacteria (107 or 108 CFU/mouse) were
inoculated by intravenous routes (i.v.). LPS (250 μg,
~10 mg/Kg) (Sigma-Aldrich Milan), or an equivalent
volume of sterile 0,9% saline vehicle (250 μl) was admi-
nistered intraperitoneally. Blood samples were drawn
from the tail vein using 0.5 ml syringes. Spleen and kid-
ney were collected at several time points (4,5,7,8,10,
11and 12 days) after the mice infection with a sub-lethal
dose of Staphylococcus epidermidis (107 CFU/mouse).
However the same organs were also collected at 3, 6, 9
Figure 5 (A) Using flow cytometry, CD64 levels were measured at 3, 6 and 9 hours after treatment in blood samples from mice
infected with Staphylococcus epidermidis (108 CFU/mouse), from mice infected with Staphylococcus.epidermidis (108 CFU/mouse) and
treated either with MIX (RJI-C at 9 μg/mouse and TB-KK at 6 μg/mouse) or with gentamicin (5 μg/mouse). (B) mRNA expression level of
COX-2, measured in kidneys of Staphylococcus.epidermidis (108 CFU/mouse ) infected mice and in kidneys of Staphylococcus epidermidis
(108 CFU/mouse) infected mice and treated with MIX (RJI-C at 9 μg/mouse and TB-KK at 6 μg/mouse) or gentamicin (5 μg/mouse) . *p <0.05,
**p < 0.01; ***p < 0.001, Student’s t test gentamicin vs MIX.
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ylococcus epidermidis (108 CFU/mouse). Spleens and
kidneys were dissected and weighed. One g of each sam-
ple was homogenized in 1 ml saline and serially diluted
in saline.
Colony forming units (CFU) were evaluated by the
plate count assay. Animal experiments were approved by
the Animal Care Committee of the University of Naples.
Measurement of cell viability
Analysis of cell viability was performed using the CellTi-
ter 96W AQueous One Solution Cell Proliferation Assay
system (MTS assay) (Promega, Madison,WI, USA). J774
cells were seeded at 2500 cells per well in a 96-well plate
and incubated at 37°C, in a humidified atmosphere with5% CO2. TB-KK 15 μg/ml, RJI-C 15 μg/ml, MIX (TB-KK
6 μg/ml + RJI-C 9 μg/ml) or RJII-C (Control 15 μg/ml)
were added to the medium immediately after cell ad-
hesion. At each time point 20 μl of CellTiter 96W
AQueous One Solution reagent was added to each
well, according to the manufacturer's instructions.
Absorbance was recorded at 490 nm after 2 h using
an EnVision 2102 multilabel reader (PerkinElmer,
Waltham, USA).
Nitrite formation in J774 cells stimulated with LPS and
treated with RJI-C, TB-KK, and the MIX
Nitrite accumulation (NO2
−, μmol/106 cells) in the cell
culture medium was determined by the Griess reac-
tion [38].
Figure 6 Haematoxylin eosin staining. Kidney sections from
Staphylococcus epidermidis (108 CFU/mouse) infected mice after 3 or
9 hours (panel 1and 5); kidney sections from Staphylococcus
epidermidis (108 CFU/mouse) infected mice after 3 hours and treated
with MIX (RJI-C at 9 μg/mouse and TB-KK at 6 μg/mouse) for 3,
6 and 9 hours (panel 2–4).
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Cell lysates for Western blotting were prepared by wash-
ing cells twice with ice-cold phosphate-buffered saline
followed by cell lysis in 500 μl of Fastprep lysis buffer
(1X protease inhibitor cocktail tablet (Roche EDTA free)
resuspended in 1X PBS) on ice and lysed 20s at 6.5 in-
tensity, 2X intervalling with 5–10 minutes on ice. Cell
lysates were centrifuged for 10 min at 7800 g at 4°C, and
the supernatants were collected and stored at −80°C until
analysis. Lysate protein concentrations were measured
using the Bio-Rad protein assay method, as described in
the manufacturer’s instructions. Cell lysate volumes cor-
responding to 20 μg of total protein were diluted 1:1 inLaemmli buffer (Bio-Rad) and boiled for 5 min prior to
electrophoresis on a 10% acrylamide gel. The resolved
proteins were electroblotted on PVDF membrane (Bio-
Rad) by the Bio-Rad semidry transfer method, according
to the manufacturer’s instructions. Membranes were
stained with PonceauRed to verify uniform protein trans-
fer, and then blocked with blocking buffer (1X TBS, 0.1%
Tween-20, 5% w/v non-fat dry milk) for 1 h at RT.
Blocked membranes were incubated overnight at 4°C
with COX-2 mouse monoclonal antibody (diluted 1/
2000), β-actin mouse monoclonal antibody (diluted 1/
10,000). Blots were washed three times in TBS-Tween
before incubation with the appropriate horseradish
peroxidase-conjugated secondary antibody (sheep anti-
mouse IgG diluted 1/5000) for 1 h at room temperature.
After three washes with TBS-Tween, the signal was
developed using standard procedure. Gel image was
acquired in Fujifilm LAS-3000 Chemiluminescence sys-
tem (Fujifilm Life science).
Real time PCR of pro-inflammatory
Total RNA was isolated from the tissue and the cell line
after treatment by using Trizol reagent (Invitrogen,
Milan, Italy). RNA was suspended in RNase-DNAse free
distilled water, assessed for concentration (by measuring
the absorbance at 260 nm) and purity (by ascertaining
that the A260/A280 ratio was .1.9). RNA (1 μg) was then
treated with 1U RNAse-free DNAse (Promega, Madison,
WI). DNA contamination of RNA samples was excluded
by PCR with primers specific for the gapdh gene. Re-
verse transcription was carried out with ImProm-II re-
verse transcriptase (Promega, Madison, WI) and oligo
(dT). Real-time PCR was performed on 50 ng cDNA,
using 1x master mix SYBRGreen (Applied Biosystem,
Milan) in a StepOne Applied Biosystem instrument
(Applied Biosystem, Milan). Reactions were performed
in 20 μl in triplicate. The primer list is reported in
Additional file 7: Table S4.
ELISA test of pro-inflammatory cytokines
In addition, the ELISA test was used to measure the
anti-inflammatory activity of the MIX and its compo-
nents : RJI-C 9 μg/mL e TB-KK 6 μg/mL.
Briefly, J774 cells (106 cells/well) were stimulated with
LPS (10 μg/ml; 1 hour), treated with RJI-C 9 μg/ml or
TB-KK 6 μg/ml or MIX (RJI-C 9 μg/ml + TB-KK 6 μg/ml)
in presence or absence of LPS (10 μg/ml). The super-
natants from these cells (100 μl/well) were transferred
into the wells of a plate previously coated with mouse
anti-human TNF-α (BD Pharmingen; 50 μl diluted 2 x
10-3/well) or mouse anti-human IFN-γ (Biosciences,
50 μl diluted 2 x 10-3/well) along with a second dose of
anti IFN- γ or TNF- α, HRP-labelled rabbit anti mouse
IgG diluted 10-3 (100 μl/well) and TMB peroxidase
Figure 7 (A-B) Bacterial load in spleen and kidneys of animals (24/groups) infected with Staphylococcus epidermidis (107 CFU/mouse;
rumble line); infected with Staphylococcus epidermidis(107 CFU/mouse) and treated with the MIX (RJI-C at 9 μg/mouse and TB-KK at
6 μg/mouse; square line) or gentamicin (5 μg/mouse; triangle line) *P <0.05, **p < 0.01; ***p < 0.001, Student’s t test gentamicin vs
MIX. (C) TNF-α, IFN-γ, IL-10 mRNA expression levels were quantified, at the indicated time points, in mice infected with Staphylococcus epidermidis
(107 CFU/mouse) or infected with Staphylococcus epidermidis (107 CFU/mouse) and treated with three different doses (I,II,III) of the MIX (RJI-C at
9 μg in 100 μl/mouse and TB-KK at 6 μg in 100 μl/mouse) or gentamicin (5 μg in 100 μl/mouse). Values were normalized with GAPDH and
compared to untreated control. *P <0.05, **p < 0.01; ***p < 0.001, Student’s t test gentamicin vs MIX.
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tical density of each well was read at 405 nm using a
microplate reader (Bio-Rad, Japan). Triplicate positive
and negative controls were included in each plate [39].
Cytofluorimetric analysis
CD64 expression in total White Blood Cells was ana-
lyzed using a Flow cytometry EPICS Elite (BeckmanCoulter, Fullerton, CA). Daily instrument quality control
including fluorescence standardization, linearity assess-
ment, and spectral compensation were performed to en-
sure identical operation from day to day. At least 10.000
events for each sample was analyzed and the data were
saved for later analysis on EXPO32 software (Beckman
Coulter). Data analysis was performed by using elec-
tronic gating on the basis of FSC and SSC excluded
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mouse CD64 expression was measured using a log10
scale. Briefly, 50 ul of whole blood was incubated for
10 minutes at room temperature with saturating
amounts of phycoeritrine- conjugated anti-CD64 mur-
ine monoclonal antibody (Becton Dickinson) followed
by red blood cell lysis with an ammonium chloride–
based red cell lysis solution (Beckman Coulter, Fuller-
ton, CA). Samples were then washed once and resus-
pended with phosphate-buffered saline at pH 7.4, to a
volume of 1 mL.
Other methods
The kidney was fixed in 10% buffered formalin, sec-
tioned (10 μm) and stained with hematoxylin-eosin
according to standard protocols. Bacterial counts and
cytokine levels were analyzed using Student’s t test.
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Additional file 1: Table S1. Lethal concentration (LC50) of Temporin
B –KK, Royal jelleins-IC, MIX through their hemolytic activity on mouse
erythrocytes.
Additional file 2: Figure S1. Anti-inflammatory activity. The levels of
IFN- γ and TNF- α were determined by a sandwich ELISA test in J774
cells untreated; J774 cells infected with S. epidermidis for 1 h; J774 cells
stimulated with RJI-C (9 μg/ml) for1 h; J774 cells stimulated with TB-KK.
(6 μg/ml) for1 h; J774 cells stimulated with MIX (RJI-C 9 μg/ml + TB-KK
6 μg/ml) for1 h; J774 cells infected with S. epidermidis for 1 h and
stimulated with MIX for 1 h. Results from two representative experiments
are presented as mean value ± S.D. *P <0.05, **p < 0.01; ***p < 0.001,
Student’s t test S. epidermidis vs S. epidermidis + MIX.
Additional file 3: Figure S2 (A-B). Bacterial load in spleen and kidneys
of S. epidermidis infected mice (rumble line) and subsequently treated
with the MIX (square line) or gentamicin (triangle line). Data are
representative of 15 animals/group. Student’s
t test gentamicin vs MIX not significant.
Additional file 4: Table S2. Acute phase proteins. Acute phase proteins
from blood samples of mice infected with Staphylococcus epidermidis and
treated with MIX or with Gentamicin.
Additional file 5: Figure S3. Time course (30, 60, 90 and 120 minutes)
of bacterial load in blood of S. epidermidis infected mice.
Additional file 6: Table S3: Origin of S. epidermidis strains.
Additional file 7: Table S4: Sequences of the primers.
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